The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
批准号:
8811012
负责人:
Subhajit Chakravorty
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-01-01 至 2018-12-31
关键词:
AbateAbstinenceAccountingAddressAftercareAge of OnsetAlcohol dependenceAlcoholismAlcoholsAnxietyBackBeck depression inventoryBiological MarkersClinicalCognitive TherapyCohort StudiesDataDisease remissionElectroencephalographyEquipment and supply inventoriesEvaluationExhibitsFamilyFamily history ofFatigueGeneral PopulationGeneralized Anxiety DisorderGeneticGoalsHealthHeavy DrinkingHourHygieneIncidenceIndividualInterventionInvestigationLaboratoriesLeadMaintenanceMeasuresMilitary PersonnelModalityMoodsOutcomeOutcome MeasureParticipantPatientsPerformance at workPharmaceutical PreparationsPharmacotherapyPhenotypePlacebosPopulationPrevalencePrimary Health CareProtocols documentationQuestionnairesRandomizedRecording of previous eventsRecoveryRecurrenceRegimenRelapseRelative (related person)Replacement TherapyResearchRiskRisk FactorsSamplingSeveritiesSeverity of illnessSleepSleeplessnessStimulusTestingTimeTimeLineTrainingTrazodoneTreatment outcomeVeteransWithdrawalalcohol cravingalcohol misusealcoholism therapyanxiety symptomsawakebasebinge drinkingclinical effectclinically significantcravingdaily functioningdepressive symptomsdesensitizationdesigndiariesdrinkingeffective therapyexperiencefallsfollow-upgabapentinhealth related quality of lifeimprovedindexingmalemodifiable riskpost interventionprimary outcomeproblem drinkerpublic health relevancerecidivismsleep regulationsobrietytargeted treatmenttraittreatment adherencetreatment effecttreatment responsetrend
中文摘要
酗酒和失眠在退伍军人中非常普遍。估计有6.4%的人酗酒
英文摘要
Alcoholism and insomnia are highly prevalent in Veterans. Alcoholism is estimated to occur in about 6.4% of
Veterans. More recent estimates of alcohol misuse range from 11.8% in OIF Veterans to 21.8% in OEF/OIF
male Veterans. Insomnia is estimated to occur in about 28% of active duty military personnel (from the
Millennium Cohort Study), and up to 77% of Veterans seen in a VHA primary care experience clinically
significant levels of insomnia. Insomnia is also highly prevalent in patients recovering from alcoholism with as
many as 70% of such patients complaining of sleep initiation and/or maintenance problems. These prevalence
rates are 2-7 times higher than that of the general population. The direct consequences of insomnia include
sleepiness, fatigue, irritability, diminished work performance and impaired interpersonal functioning. The long-
term sequelae of insomnia include risk for new-onset and recurrent psychiatric illness, and in the context of
alcoholism, greater intensity of alcoholism and increased risk for relapse in abstinent alcoholics. At present,
there are nine studies which evaluate whether insomnia represents a modifiable risk factor for relapse of
alcoholism (2 investigating trazodone, 3 investigating gabapentin, 1 investigating ramelteon, and 3
investigating a modified form of cognitive-behavioral therapy for insomnia [CBT-I]). The results from these
studies are variable. The CBT-I investigations show the most promise in terms of improved sleep, but there is
no clear evidence that improved sleep has protective value against pathological drinking. Accordingly, CBT-I
(n=30) will be evaluated and compared to the Quasi-Desensitization Therapy (QDT) (n=30) in a sample of
veterans who have been sober for at least one month (but less than one year). The study cohort will be further
stratified into those who do (n=30) and do not (n=30) have a first-degree family history of alcoholism. Familial
alcoholism is taken into account, as this may represent a unique factor that contributes to insomnia severity
and/or treatment outcome. All subjects will complete a 2-week baseline recording period followed by weekly
CBT-I/QDT sessions for 8-weeks. CBT-I will be conducted according to a standard protocol. Weekly 1-hour
sessions (individual format) will be used to deliver the four components of CBT-I (Sleep Restriction, Stimulus
Control, Sleep Hygiene, and Cognitive therapy [sleep-related de-catastrophization]). Treatment will be followed
up with two evaluations at 3 and 6 months post-intervention. All subjects will complete the Insomnia Severity
Index, daily sleep diaries, and the alcohol-related measures for a 2-week baseline, for the intervention period,
and for two follow-up intervals after treatment completion at 3 and 6 months. The primary outcome measures
are insomnia severity (as assessed with the ISI) and percentage days abstinent (as assessed using the
Timeline Follow Back measure). In addition, health and mood will be tracked using the Short Form-12 (SF-12)
item scale, the BDI-II, PHQ9, STAI, and the GAD7. The combination of these measures serve to test the
hypotheses that standard CBT-I can be applied successfully in patients recovering from alcoholism and that
successful treatment of insomnia will be associated with better clinical outcomes in relation to alcoholism.
Finally, family history data will be assessed on an exploratory basis to assess differences in baseline insomnia
and objective sleep, as well as outcomes for the insomnia, alcoholism, treatment adherence, and/or treatment
outcome. Objective sleep will be preliminarily assessed with in-laboratory polysomnograms of seven subjects
with and without familial alcoholism (n=16). It is hypothesized that CBT-I in abstinent alcoholics will lead to 1)
significantly superior sleep-related outcomes as compared to QDT, 2) pre-to-post treatment effect sizes that
are comparable to the meta-analytic norms, 3) a larger percentage of days abstinent with at least a trend
toward fewer relapses, and 4) better overall health and mood. If these findings are achieved and replicated, it
will suggest that insomnia treatment should be a standard component in the management of alcoholism and
that CBT-I is an ideal management approach for this co-morbid insomnia.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
-
批准号:10013402
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Subhajit Chakravorty
-
依托单位:
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
-
批准号:10578700
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Subhajit Chakravorty
-
依托单位:
Cognitive Behavioral Therapy (CBT-I) Augmentation of Topiramate in promoting abstinence in alcohol use disorder (AUD).
-
批准号:10394786
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Subhajit Chakravorty
-
依托单位:
The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
-
批准号:8634474
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Subhajit Chakravorty
-
依托单位:
The Efficacy of CBT-I in Alcoholics & Its Effects on Remission & Relapse
-
批准号:9240571
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2014
-
负责人:Subhajit Chakravorty
-
依托单位:
海外基金